Comparative Pharmacology
Head-to-head clinical analysis: BREO ELLIPTA versus OTOBIONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREO ELLIPTA versus OTOBIONE.
BREO ELLIPTA vs OTOBIONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.
OTOBIONE is a combination product containing ciprofloxacin (a fluoroquinolone antibiotic) and fluocinolone acetonide (a corticosteroid). Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, leading to bacterial cell death. Fluocinolone acetonide suppresses inflammation by binding to glucocorticoid receptors, inhibiting phospholipase A2, and reducing prostaglandin and leukotriene synthesis.
One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.
1-2 drops in affected ear(s) twice daily; otic administration only.
None Documented
None Documented
Fluticasone furoate: 24 hours (supports once-daily dosing). Vilanterol: 11 hours (supports once-daily dosing).
2.5 hours (prolonged to 12-24 hours in renal impairment, CrCl <30 mL/min)
Fluticasone furoate is eliminated primarily via fecal excretion (approximately 101% of an oral dose) due to biliary clearance, with minimal renal excretion (<1%). Vilanterol is eliminated via metabolism and subsequent renal (approximately 70% of an IV dose) and fecal (approximately 30% of an IV dose) excretion.
Renal: 90% unchanged; biliary: <5% as metabolites; fecal: <2%
Category C
Category C
Corticosteroid/Beta-2 Agonist Combination
Otic Antibiotic/Corticosteroid